News

In this Q&A, Vinod Chandran, MBBS, MD, DM, PhD, discussed a method to analyze biomarkers that may differentiate patients with psoriasis and psoriatic arthritis.

A network meta-analysis lends "compelling" support to the practice of switching patients with RA from biologics to less costly biosimilars at 6 months.

This retrospective study from Japan highlighted several key elements linked to a generalized pustular psoriasis diagnosis among individuals with psoriasis vulgaris.

Patients with fibromyalgia receiving CBT experienced significant improvements in pain interference and larger decreases in pain catastrophizing post-treatment.

Study links inflammatory bowel disease diagnosis to increased gout risk, with Crohns disease and ulcerative colitis linked to 68% and 38% increases in likelihood of developing gout, respectively, relative to counterparts without IBD.

Fatigue was positively correlated with the frequency, duration, severity, and chronicity of migraine episodes, as well as excessive daytime sleepiness.

This small study found DNA methylation profiles in CD4+ T-cells may represent a stable and reliable biomarker.

Significantly greater improvements in back pain and morning stiffness were observed in patients receiving ixekizumab compared with placebo.

Males in the highest serum uric acid tier were significantly more likely to be diagnosed with peripheral artery disease, although a similar trend was not observed in female patients.

The incidences of stroke, ischemic heart disease, or heart failure were slightly higher in patients with gout when compared with controls.

Continued reductions in serum acute phase proteins and collagen degradation proteins observed in patients with psoriatic arthritis receiving guselkumab may be linked to sustained symptom improvements.

An interim analysis from the UPJOINT trial provides insight into the effects of upadacitinib use in real-world settings among patients with oligo- or polyarticular psoriatic arthritis.

Investigators believe a more consistent application of disease activity measures may help to guide treatment decisions and improve quality of care.

Significantly more patients receiving voclosporin had a good renal outcome, defined as achieving adequate response with no renal flare, compared with controls.

A lower proportion of patients in the belimumab treatment group experienced ≥1 kidney flare compared with placebo in the overall population.

Patients with IBD-RA and depression were younger, more likely to be female, and were more frequently White compared with controls.

A higher number of patients receiving guselkumab treatment reported ≥1 improvement as early as week 4, which continued to improve through week 24.

A nationwide cohort study shows individuals with a history of infection are at a nearly 50% greater likelihood of dementia development in older age.

A meta-analysis of 7 prospective or retrospective cohort studies conducted in Asia and Europe suggests a diagnosis of gout or hyperuricemia was linked to a lower risk of Alzheimer disease.

After stratifying for gender, age, and ethnicity, hyperuricemia remained positively associated with nephrolithiasis.

Patients receiving TNF, JAK, and CTLA4-Ig all demonstrated higher discontinuation rates due to ineffectiveness when compared to aIL-6R treatment.

Markets with an increased number of rheumatologists had lower costs per patient for emergency room visits and hospitalization compared to areas with a low supply.

A low certainty of clinically relevant positive effects of aerobic and mixed exercise training for reducing mobility difficulties was observed in patients with fibromyalgia at the end of the intervention.

The subscales presenting the highest scores in patients with fibromyalgia were foot pain and symptom intensity.

Cardiorespiratory and muscular parameters were improved after exercise rehabilitation in patients with long COVID, patients with fibromyalgia, and those with coronary artery disease.

Reduced 12-month drug retention rates were seen in patients with concurrent use of hydroxychloroquine, intravenous bDMARD use, and a history of discontinuation of the drug within the first 3 months of the pandemic.

On August 29, 2023, the Biden Administration debuted the list of the first 10 drugs identified for price negotiation under the Inflation Reduction Act. The list, which includes agents indicated for diabetes, heart failure, GI conditions, and arthritis, accounted for more than $50 billion in spending during the evaluation period.

The strongest predictors of hyperuricemia were body mass index, lipid accumulation product, and visceral adiposity index.

No statistical differences in pain or quality of life were observed between patients with fibromyalgia receiving posterior tibial nerve stimulation intervention and controls.

Real-world analyses help patients and their healthcare providers make more informed and personalized treatment decisions with the goal of long-term symptomatic relief.